Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001

Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding… Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding US. Proveca has been granted a non-exclusive option to license Cessatech’s CT002 program. Proveca is a global pharmaceutical company specialising in the development and licensing of medicines to address the unmet medical needs in children. Proveca is based in Manchester, England. On 26 August – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company has entered into an exclusive commercialization agreement with Proveca Ltd – a global pharmaceutical company which specialises in the development and licensing of medicines to address the unmet medical needs in children – for the commercialization of CT001 world-wide with an emphasis on Europe and major markets elsewhere. Under the agreement Proveca will be the marketing authorization holder. This agreement leverages the Proveca team’s expertise in specialised medicines for children and their strong experience with PUMA licensing (Paediatric Use Marketing Authorisation) in Europe, which today includes four PUMA approvals. The detailed terms of the agreement is not disclosed but includes an upfront payment upon signature and double-digit royalties to Cessatech on the basis of net sales in the licensed territory. Jes Trygved, CEO Cessatech “We are extremely pleased with this agreement, and the partnership with Proveca – a company that in many ways share the same vision, ‘caring about the medication for children’. From the first meetings we had with Proveca, we knew this was an interesting opportunity and someone who spoke the same language. Financially, this agreement is a very strong asset, and it gives us opportunities to expand our pipeline further and provide more solutions for children – an area that is still not prioritized enough. We are truly excited about the partnership.” Simon Bryson, CEO Proveca “This partnership between Proveca and Cessatech is founded on our shared ambition to improve the lives of children globally with innovative medicines to address their unmet medical needs. We’re excited to embark on our first collaboration with Cessatech as we take CT001 through the next phase of its journey, building on the extensive R&D programme, to register and commercialise the product globally. With projected potential peak sales in the high double digit million euros, this is a significant milestone deal for both companies, and we look forward to extending the partnership further with other opportunities, including CT002 for medical procedural sedation in children.” About Proveca Proveca Ltd is a UK-founded, global, commercial stage pharmaceutical company, with technical and commercial operations across Europe, and a global commercialisation platform. The company specialises in the development, licensing and commercialisation of evidence-based medicines to address the unmet medical needs of children, with a current paediatric product portfolio within the neurology, cardiovascular, gastroenterology and immunology therapeutic areas Link to Release https://cessatech.com/wp-content/uploads/2024/08/JT_Proveca.mp4 Related articles Releases 27. August, 2026 CT001 ready for shipment to initial U.S. hospitals as launch activities commence Initial U.S. commercial supply of CT001 now available for shipment Launch activities initiated with... Read more Releases 24. July, 2026 Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu See also the updated Q&A documentation related to the Release: Link The European Medicines... Read more Releases 12. June, 2026 Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children ... Read more Stay up to date! Subscribe and get notified on Cessatech's latest news. An acceptance email will be sent to you, please check your spam. Please leave this field empty Almost there! Please check your inbox to confirm your subscription to Cessatech.

The release as fetched from its publisher. cessatech.com ↗